Skip to main content
SpringerLink
Log in

Antimicrobial Resistance: An International Public Health Problem

  • Chapter
  • First Online:
Antimicrobial Drug Resistance

Abstract

In recent years, the problem of antimicrobial resistance has been recognized and addressed by international, regional, and national public health agencies, authorities, and professional societies [1–4]. Antibiotics have saved millions of lives and have enabled many other medical advances since their discovery and introduction into clinical practice. The worsening problem of antimicrobial resistance now jeopardizes many of these advances. However, action plans to minimize this threat have been developed by many public health agencies around the globe [5–8]. This focus is likely to increase among public health agencies in the coming years. Several facets of the problem involve the relationship between human and animal use of antimicrobial agents [3, 9]. This chapter summarizes the components of the cost of resistance from a public health perspective and contrasts this perspective to other societal perspectives. It then reviews strategies at several different levels of responsibility, ranging from the patient care provider to international agencies. Finally, it considers appropriate public health responses according to the resources available for control. In an era of globalization, antimicrobial resistance represents an international concern that demands a concerted effort from multiple health and industry sectors. Public health must be at the forefront of these efforts. Antimicrobial resistance is widely recognized as a complex international problem. Antibiotics have saved millions of lives and have enabled many other medical advances since their discovery and introduction into clinical practice. The worsening problem of antimicrobial resistance now jeopardizes many of these advances [1, 2, 4, 7, 8, 10–13]. The number of pathogens resistant to multiple classes of antimicrobials has increased worldwide [14]. There have been reports of infections with Pseudomonas aeruginosa and Acinetobacter species which are resistant to all available antibiotics [15]. Other pathogens, such as Neisseria gonorrhoeae, that were previously relatively easy to treat, are now becoming much more difficult to treat due to antimicrobial resistance [16]. There is also evidence that resistant organisms that were previously confined to the acute care hospital setting are now sources of community-acquired infections [17]. Resistance is not only an issue for bacterial pathogens like staphylococci, enterococci, Escherichia coli, Klebsiella, Neisseria, and Mycobacterium tuberculosis but also the problem of resistance that is increasingly being recognized in nonbacterial pathogens like Candida, HIV, malaria, and influenza [14].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bell M. Antibiotic misuse: a global crisis. JAMA Intern Med. 2014;174:1920–1.

    Article  PubMed  Google Scholar 

  2. Carlet JM, Artigas A, Niederman MS, Torres A, World Alliance against Antibiotic Resistance. The Barcelona declaration from the world alliance against antibiotic resistance: engagement of intensivists. Crit Care. 2012;16:145.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goosens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2014;13:1057–98.

    Article  Google Scholar 

  4. Shallcross LJ, Davies SC. The World Health Assembly resolution on antimicrobial resistance. J Antimicrob Chemother. 2014;69:2883–5.

    Article  CAS  PubMed  Google Scholar 

  5. CDC. Antibiotic resistance threats in the United States. (2013). http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 11 Dec 2014.

  6. Kessel AS, Sharland M. The new UK antimicrobial resistance strategy and action plan. BMJ. 2013;346:f1601.

    Article  PubMed  Google Scholar 

  7. Keown OP, Warburton W, Davies SC, Darzi A. Antimicrobial resistance: addressing the global threat through greater awareness and transformative action. Health Aff (Millwood). 2014;33:1620–6.

    Article  Google Scholar 

  8. Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int J Antimicrob Agents. 2013;42:S25–8.

    Article  CAS  PubMed  Google Scholar 

  9. McIntosh D, Dean W. Factors associated with the inappropriate use of antimicrobials. Zoonoses Public Health. 2014;61:1–7.

    Google Scholar 

  10. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N’Doye B, Pittet D, Richtmann R, Seto WH, van der Meer JWM, Voss A. Society’s failure to protect a precious resource: antibiotics. Lancet. 2011;378:369–71.

    Article  PubMed  Google Scholar 

  11. Speck P. Antibiotics: avert an impending crisis. Nature. 2013;496:169.

    Article  CAS  PubMed  Google Scholar 

  12. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368:299–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Woolhouse M, Farrar J. An intergovernmental panel on antimicrobial resistance. Nature. 2014;509:555–7.

    Article  PubMed  Google Scholar 

  14. WHO. Antimicrobial resistance: global report on surveillance. (2014). http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf. Accessed 11 Dec 2014.

  15. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006;43:S43–8.

    Article  PubMed  Google Scholar 

  16. Ndowa FJ, Ison CA, Cole MJ, Lusti-Narasimhan M. Gonococcal antimicrobial resistance: challenges for public health control. Sex Transm Infect. 2013;89:iv3–4.

    Article  PubMed  Google Scholar 

  17. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, Lessa FC, Lynfield R, Nadle J, Petit S, Ray SM, Schaffner W, Townes J, Fridkin S, Emerging Infections Program-Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173:1970–8.

    PubMed  Google Scholar 

  18. DiazGranados CA, Cardo DM, McGowan Jr JE. Antimicrobial resistance: international control strategies, with a focus on limited-resource settings. Int J Antimicrob Agents. 2008;32:1–9.

    Article  CAS  PubMed  Google Scholar 

  19. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42:S82–9.

    Article  PubMed  Google Scholar 

  20. Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, Larson EL. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55:807–15.

    Article  PubMed  PubMed Central  Google Scholar 

  21. McGowan Jr JE. Economic impact of antimicrobial resistance. Emerg Infect Dis. 2001;7:286–92.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Roberts RR, Hota B, Ahmad I, Scott 2nd RD, Foster SD, Abbasi F, Schabowski S, Kampe LM, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175–84.

    Article  PubMed  Google Scholar 

  23. White AR, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother. 2011;66:1948–53.

    Article  CAS  PubMed  Google Scholar 

  24. Laxminarayan R. Antibiotic effectiveness: balancing conservation against innovation. Science. 2014;345:1299–301.

    Article  CAS  PubMed  Google Scholar 

  25. Laxminarayan R, Malani A. Extending the cure: policy responses to the growing threat of antibiotic resistance. (2007). http://www.cddep.org/publications/extending_cure_policy_responses_growing_threth_antibiotic_resistance. Accessed 11 Dec 2014.

  26. Institute of Medicine. The future of public health. Washington, D.C.: National Academy Press; 1988.

    Google Scholar 

  27. McGowan Jr JE. Antimicrobial stewardship—the state of the art in 2011: focus on outcome and methods. Infect Control Hosp Epidemiol. 2012;33:331–7.

    Article  PubMed  Google Scholar 

  28. Carlet J, Pittet D. Access to antibiotics: a safety and equity challenge for the next decade. Antimicrob Resist Infect Control. 2013;2:1.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Carlet J, Pulcini C, Piddock LJV. Antibiotic resistance: a geopolitical issue. Clin Microbiol Infect. 2014;20:949–53.

    Article  CAS  PubMed  Google Scholar 

  30. Choudhury R, Panda S, Singh DV. Emergence and dissemination of antibiotic resistance: a global problem. Indian J Med Microbiol. 2012;30:384–90.

    Article  CAS  PubMed  Google Scholar 

  31. Bartlett JG. A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis. 2011;53:S4–7.

    Article  PubMed  Google Scholar 

  32. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013;56:1445–50.

    Article  CAS  PubMed  Google Scholar 

  33. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–50.

    Article  PubMed  Google Scholar 

  34. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52:813–21.

    Article  CAS  PubMed  Google Scholar 

  35. de Kraker MEA, Davey PG, Grundmann H, Burden study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8, e1001104.

    Article  PubMed  PubMed Central  Google Scholar 

  36. de Kraker MEA, Wolkewitz M, Davey PG, Grundmann H, Burden Study Group. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2011;55:1598–605.

    Article  PubMed  PubMed Central  Google Scholar 

  37. de Kraker MEA, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, Kaasch A, Paniara O, Argyropoulou A, Bompola M, Smyth E, Skally M, Raglio A, Dumpis U, Kelmere AM, Borg M, Xuereb D, Ghita MC, Noble M, Kolman J, Grabljevec S, Turner D, Lansbury L, Grundmann H. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66:398–407.

    Article  PubMed  Google Scholar 

  38. Lode HM. Clinical impact of antibiotic-resistant gram-positive pathogens. Clin Microbiol Infect. 2009;15:212–17.

    Article  CAS  PubMed  Google Scholar 

  39. Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, Badri M, Lesosky M, van Helden P, Sirgel FA, Warren R, Dheda K. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383:1230–9.

    Article  PubMed  Google Scholar 

  40. Pop-Vicas A, Opal SM. The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock. Virulence. 2014;5:189–95.

    Article  Google Scholar 

  41. Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, Phelan M, Facklam RR, Cetron MS, Breiman RF, Kolczak M, Schuchat A. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis. 2001;33:797–805.

    Article  CAS  PubMed  Google Scholar 

  42. Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2006;42:788–97.

    Article  PubMed  Google Scholar 

  43. Lemos EV, de la Hoz FP, Alvis N, Einarson TR, Quevedo E, Castañeda C, Leon Y, Amado C, Cañon O, Kawai K. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Columbia. Clin Microbiol Infect. 2013;20:174–80.

    Article  PubMed  Google Scholar 

  44. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.

    Article  PubMed  Google Scholar 

  45. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993–8.

    Article  CAS  PubMed  Google Scholar 

  46. Marks SM, Flood J, Seaworth B, Hirsch-Moverman Y, Armstrong L, Mase S, Salcedo K, Oh P, Graviss EA, Colson PW, Armitige L, Revuelta M, Sheeran K, TB Epidemiologic Studies Consortium. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20:812–20.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Adler A, Hussein O, Ben-David D, Masarwa S, Navon-Venezia S, Schwaber MJ, Carmeli Y, Post-Acute-Care Hospital Carbapenem-Resistant Enterobacteriaceae Working Group. Persistence of Klebsiella pneumoniae ST258 as the predominant clone of carbapenemase-producing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008–2013. J Antimicrob Chemother. 2015;70:89–92.

    Article  CAS  PubMed  Google Scholar 

  48. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013;62:499–513.

    Article  CAS  PubMed  Google Scholar 

  49. Manenzhe RI, Zar HJ, Nicol MP, Kaba M. The spread of carbapenemase-producing bacteria in Africa: a systematic review. J Antimicrob Chemother. 2015;70:23–40.

    Article  CAS  PubMed  Google Scholar 

  50. Morris D, Boyle F, Morris C, Condon I, Delannoy-Vieillard AS, Power L, Khan A, Morris-Downes M, Finnegan C, Powell J, Monahan R, Burns K, O’Connell N, Boyle L, O’Gorman A, Humphreys H, Brisse S, Turton J, Woodford N, Cormican M. Inter-hospital outbreak of Klebsiella pneumoniae producing KPC-2 carbapenemase in Ireland. J Antimicrob Chemother. 2012;67:2367–72.

    Article  CAS  PubMed  Google Scholar 

  51. Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N. Dominance of international ‘high-risk clones’ among metallo-β-lactamase-producing Pseudomonas aeruginosa in the UK. J Antimicrob Chemother. 2015;70:103–10.

    Article  CAS  PubMed  Google Scholar 

  52. Lee GM, Kleinman K, Soumerai SB, Tse A, Cole D, Fridkin SK, Horan T, Platt R, Gay C, Kassler W, Goldmann DA, Jernigan J, Jha AK. Effect of nonpayment for preventable infections in U.S. hospitals. N Engl J Med. 2012;367:1428–37.

    Article  CAS  PubMed  Google Scholar 

  53. Lee GM, Hartmann CW, Graham D, Kassler W, Linn MD, Krein S, Saint S, Goldmann DA, Fridkin S, Horan T, Jernigan J, Jha A. Perceived impact of the medicare policy to adjust payment for health care-associated infections. Am J Infect Control. 2012;40:314–19.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents. 2012;39:283–94.

    Article  CAS  PubMed  Google Scholar 

  55. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601.

    Article  CAS  PubMed  Google Scholar 

  56. Finley RL, Collignon P, Joakim Larsson DG, McEwen SA, Li XZ, Gaze WH, Reid-Smith R, Timinouni M, Graham DW, Topp E. The scourge of antibiotic resistance: the important role of the environment. Clin Infect Dis. 2013;57:704–10.

    Article  PubMed  Google Scholar 

  57. Davey P, Sneddon J, Nathwani D. Overview of strategies for overcoming the challenge of antimicrobial resistance. Expert Rev Clin Pharmacol. 2010;3:667–86.

    Article  PubMed  Google Scholar 

  58. Lee CR, Cho IH, Jeong BC, Lee SH. Strategies to minimize antibiotic resistance. Int J Environ Res Public Health. 2013;10:4274–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Gould IM. Antibiotic resistance: understanding how to control it. Int J Antimicrob Agents. 2012;40:193–5.

    Article  CAS  PubMed  Google Scholar 

  60. Hand K. Antibiotic stewardship. Clin Med. 2013;13:499–503.

    Article  Google Scholar 

  61. Leuthner KD, Doern GV. Antimicrobial stewardship programs. J Clin Microbiol. 2013;51:3916–20.

    Article  PubMed  PubMed Central  Google Scholar 

  62. O’Brien DJ, Gould IM. Maximizing the impact of antimicrobial stewardship: the role of diagnostics, national and international efforts. Curr Opin Infect Dis. 2013;26:352–8.

    Article  PubMed  Google Scholar 

  63. Pile JC. Antimicrobial stewardship: optimizing antibiotic use in an era of increasing resistance and rising costs. J Hosp Med. 2011;6:S1–3.

    Article  PubMed  Google Scholar 

  64. Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM, The Infectious Diseases Society of America Emerging Infections Network. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32:367–74.

    Article  PubMed  Google Scholar 

  65. Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am. 2011;25:245–60.

    Article  PubMed  Google Scholar 

  66. Amadeo B, Dumartin C, Parneix P, Fourrier-Réglat A, Rogues AM. Relationship between antibiotic consumption and antibiotic policy: an adjusted analysis in the French healthcare system. J Antimicrob Chemother. 2011;66:434–42.

    Article  CAS  PubMed  Google Scholar 

  67. Whiley DM, Goire N, Lahra MM, Donovan B, Limnios AE, Nissen MD, Sloots TP. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother. 2012;67:2059–61.

    Article  CAS  PubMed  Google Scholar 

  68. Frieden TR, Brudney KF, Harries AD. Global tuberculosis: perspectives, prospects, and priorities. JAMA. 2014;312:1393–4.

    Article  CAS  PubMed  Google Scholar 

  69. Chitnis AS, Edwards JR, Ricks PM, Sievert DM, Fridkin SK, Gould CV. Device-associated infection rates, device utilization, and antimicrobial resistance in long-term acute care hospitals reporting to the national healthcare safety network, 2010. Infect Control Hosp Epidemiol. 2012;33:993–1000.

    Article  PubMed  Google Scholar 

  70. Chitnis AS, Magill SS, Edwards JR, Chiller TM, Fridkin SK, Lessa FC. Trends in Candida central line-associated bloodstream infections among NICUs, 1999–2009. Pediatrics. 2012;130:e46–52.

    Article  PubMed  Google Scholar 

  71. Fagan RP, Edwards JR, Park BJ, Fridkin SK, Magill SS. Incidence trends in pathogen-specific central line-associated bloodstream infections in US intensive care units, 1990–2010. Infect Control Hosp Epidemiol. 2013;34:893–9.

    Article  PubMed  Google Scholar 

  72. Grundmann H, Klugman KP, Walsh T, Ramon-Pardo P, Sigauque B, Khan W, Laxminarayan R, Heddini A, Stelling J. A framework for global surveillance of antibiotic resistance. Drug Resist Updat. 2011;14:79–87.

    Article  PubMed  Google Scholar 

  73. Magill SS, Hellinger W, Cohen J, Kay R, Bailey C, Boland B, Carey D, de Guzman J, Dominguez K, Edwards J, Goraczewski L, Horan T, Miller M, Phelps M, Saltford R, Seibert J, Smith B, Starling P, Viergutz B, Walsh K, Rathore M, Guzman N, Fridkin S. Prevalence of healthcare-associated infections in acute care hospitals in Jacksonville, Florida. Infect Control Hosp Epidemiol. 2012;33:283–91.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Zarb P, Goosens H. European Surveillance of Antimicrobial Consumption (ESAC): value of a point-prevalence survey of antimicrobial use across Europe. Drugs. 2011;71:745–55.

    Article  PubMed  Google Scholar 

  75. Carlet J. World Alliance against antibiotic resistance (WAAR): safeguarding antibiotics. Intensive Care Med. 2012;38:1723–4.

    Article  PubMed  Google Scholar 

  76. Cully M. The politics of antibiotics. Nature. 2014;509:S16–17.

    Article  CAS  PubMed  Google Scholar 

  77. Lusti-Narasimhan M, Pessoa-Silva CL, Temmerman M. Moving forward in tackling antimicrobial resistance: WHO actions. Sex Transm Infect. 2013;89:iv57–9.

    Article  PubMed  Google Scholar 

  78. Slaughter LM. Antibiotics: support US policy change. Nature. 2013;500:400.

    Article  CAS  PubMed  Google Scholar 

  79. Magill SS, Fridkin SK. Improving surveillance definitions for ventilator-associated pneumonia in an era of public reporting and performance measurement. Clin Infect Dis. 2012;54:378–80.

    Article  PubMed  Google Scholar 

  80. Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, Fridkin S, Greene L, Guh A, Gutterman D, Hammer B, Henderson D, Hess DR, Hill NS, Horan T, Kollef M, Levy M, Septimus E, VanAntwerpen C, Wright D, Lipsett P. Developing a new national approach to surveillance for ventilator-associated events: executive summary. Am J Infect Control. 2013;41:1096–9.

    Article  PubMed  Google Scholar 

  81. Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, Fridkin S, Greene L, Guh A, Gutterman D, Hammer B, Henderson D, Hess D, Hill NS, Horan T, Kollef M, Levy M, Septimus E, VanAntwerpen C, Wright D, Lipsett P. Developing a new, national approach to surveillance for ventilator-associated events: executive summary. Clin Infect Dis. 2013;57:1742–6.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Laxminarayan R, Heymann D. Challenges of drug resistance in the developing world. BMJ. 2012;344, e1567.

    Article  PubMed  Google Scholar 

  83. Nguyen KV, Thi Do NT, Chandna A, Nguyen TV, Pham CV, Doan PM, Nguyen AQ, Thi Nguyen CK, Larsson M, Escalante S, Olowokure B, Laxminarayan R, Gelband H, Horby P, Thi Ngo HB, Hoang MT, Farrar J, Hien TT, Wertheim HFL. Antibiotic use and resistance in emerging economies: a situation analysis for Viet Nam. BMC Public Health. 2013;13:1158.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174:1914–20.

    Article  PubMed  Google Scholar 

  85. Murni I, Duke T, Triasih R, Kinney S, Daley AJ, Soenarto Y. Prevention of nosocomial infections in developing countries, a systematic review. Paediatr Int Child Health. 2013;33:61–78.

    Article  PubMed  Google Scholar 

  86. Molton JS, Tambyah PA, Ang BSP, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective of Asia. Clin Infect Dis. 2013;56:1310–18.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, 30307, USA

    Joseph D. Lutgring M.D.

  2. Clinical Department, Sanofi Pasteur, Swiftwater, PA, USA

    Carlos A. Diaz Granados M.D., M.S.C.R.

  3. Department of Epidemiology, Rollins School of Public Health, Emory University, Room CNR4009, 1518 Clifton Road, Atlanta, GA, 30322, USA

    John E. McGowan Jr. M.D.

Authors
  1. Joseph D. Lutgring M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos A. Diaz Granados M.D., M.S.C.R.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John E. McGowan Jr. M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John E. McGowan Jr. M.D. .

Editor information

Editors and Affiliations

  1. Treiber Therapeutics, Cambridge, Massachusetts, USA

    Douglas L. Mayers

  2. Wayne State University School of Medicine, Detroit Medical Center, Detroit, Michigan, USA

    Jack D. Sobel

  3. Canada Research Chair in Antimicrobial Resistance, Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

    Marc Ouellette

  4. Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

    Keith S. Kaye

  5. Infection Control and Prevention Unit of Infectious Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

    Dror Marchaim

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Lutgring, J.D., Granados, C.A.D., McGowan, J.E. (2017). Antimicrobial Resistance: An International Public Health Problem. In: Mayers, D., Sobel, J., Ouellette, M., Kaye, K., Marchaim, D. (eds) Antimicrobial Drug Resistance. Springer, Cham. https://doi.org/10.1007/978-3-319-47266-9_39

Download citation

Publish with us

Policies and ethics

Search

Navigation